Rationale Protracted use of methamphetamine (mAMPH) can result in long-term impairments in cognitive function in humans. A previous study reported reversal-specific learning impairments in rats after a binge administration of mAMPH. Several studies show that extended exposure to mAMPH may confer protection against cognitive impairments and the insult to monoamine systems typically observed after larger binge doses. Objectives To explore this issue, we compared the effects of escalating and single doses of mAMPH (and saline, SAL) on retention, reversal learning, and post-mortem analysis of dopamine and serotonin transporters, DAT and SERT. Methods Rats learned to discriminate equiluminant stimuli and then were treated with either: (1) 4 weeks of mAMPH increasing by 0.3 mg/kg, culminating in 6 mg/kg (mAMPH escal ); (2) 4 weeks of SAL with a single dose of 6 mg/kg on the last day of treatment (mAMPH single ); or (3) 4 weeks of SAL. Following treatment, rats were tested on retention and reversal learning, with subsequent analysis of DAT and SERT binding across subregions of the striatum and frontoparietal cortex, respectively. Results Retention of the pretreatment discrimination was not significantly impaired in either mAMPH treatment group. A significant decrease in ventrolateral striatal DAT binding was observed only in the mAMPH single group and frontoparietal SERT was unaffected by either mAMPH treatment. Both treatment groups demonstrated attenuated reversal learning, particularly on measures of accuracy and effort. Conclusions These results show that extended and singledose pretreatment with mAMPH similarly and selectively affect reversal learning, even in the absence of significant DAT or SERT changes.
Introduction
Use of the highly addictive psychostimulant methamphetamine (mAMPH) can result in cognitive inflexibility in humans (Hoffman et al. 2006; Verdejo-Garcia et al. 2006) and experimental animals (Izquierdo et al. 2010; Parsegian et al. 2011; Groman et al. 2012) . A lack of cognitive or inhibitory control is thought to contribute to an increased vulnerability to abuse drugs (Perry and Carroll 2008; Robinson and Berridge 2003) . Long-term drug abuse, in turn, appears to result in decreased inhibitory control (Perry and Carroll 2008; Salo et al. 2002) , typifying the complex and circuitous relationship between drug use and cognitive dysfunction (Izquierdo and Jentsch 2012; Lucantonio et al. 2012) . Monoaminergic changes in frontostriatal circuitry have been observed after experimenter-administered regimens of mAMPH in animals. Specifically, striatal dopamine (DA) depletions occur readily after single-day, moderate-to-high dose "binge" mAMPH treatment regimens Wagner et al. 1980 ) and single mAMPH injections (Fukumura et al. 1998) , with serotonergic changes in the frontoparietal cortex also found in animals treated similarly with mAMPH (O'Dell et al. 2012; Schmidt et al. 1985) .
Escalating or sensitizing dosing regimens, characterized by small doses that then gradually increase in frequency and/or size, have been used to model human users' initial escalation phase of drug use (Simon et al. 2002) . Importantly, these administration patterns can result in very different behavioral (Belcher et al. 2008 ) and neurochemical (Graham et al. 2008; Segal et al. 2003) profiles when compared to singleday dosing regimens. These administration patterns have also been known to confer a protective effect against the mAMPHinduced neurotoxicity commonly seen after single-day bingetype regimens (Graham et al. 2008; Segal et al. 2003 ) and the behavioral sequelae of these mAMPH treatment regimens can occur even in the absence of any significant DA or serotonin changes (Belcher et al. 2006; Kosheleff et al. 2011; cf. Groman et al. 2012 ). Furthermore, impairments on an object recognition task can be attenuated or prevented altogether when a single-day binge regimen is preceded by an escalating regimen (Belcher et al. 2008; Clark et al. 2007) . Less is known, however, about how these different administration patterns might affect cognitive flexibility or inhibitory control.
Reversal learning tasks, in which the main requirement is to respond to a reversal in reward contingency, are practical and confirmed assays of inhibitory control. Monoamine systems in orbitofrontal cortex and striatum that are recruited in reversal tasks are also affected by mAMPH (Izquierdo and Jentsch 2012; Lucantonio et al. 2012) . Brief, moderate-to-high doses of mAMPH are known to result in impairments on several measures of reversal: spatial reversal (White et al. 2009 ), response reversal (Cheng et al. 2007 ; cf. Daberkow et al. 2008) , and visual discrimination reversal (Izquierdo et al. 2010) learning. However, no study has directly compared the effects of single-day doses of mAMPH on reversal learning to those found after gradually escalating, prolonged administration of mAMPH. Consequently, we chose to examine three groups treated with either a single exposure to mAMPH, extended mAMPH, or saline (SAL) on reversal learning. Behavioral testing was followed by quantification of DAT in the striatum and SERT (Shepard et al. 2004) in several areas of frontoparietal cortex, including regions known to be directly affected by mAMPH (Meredith et al. 2005; Nordahl et al. 2003) and involved in cognitive flexibility (Kesner and Churchwell 2011; Ragozzino 2002; Ragozzino et al. 2002) .
Methods

Subjects
Thirty-one male Long-Evans rats (Charles River Laboratories, Raleigh, NC) weighing between 275 and 300 g at the beginning of the study were individually housed during food restriction, given water ad libitum and maintained at a 12-h light/12-h dark cycle, with the temperature at 22°C. Body weights were monitored daily. Behavioral testing took place between 0800 and 1600 hours during the rats' inactive period, consistent with previous and ongoing studies in our lab (Izquierdo et al. 2010; Kosheleff et al. 2011) . All procedures were in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council of the National Academies 2011) and approved by the Institutional Animal Care and Use Committee at California State University, Los Angeles.
Apparatus
Operant conditioning chambers [35 cm (length)×28 cm (width)×34 cm (height)] (#80004, Lafayette Instrument Co., Lafayette, IN) were housed within sound-and lightattenuating cubicles (#83018DDP, Lafayette Instrument Co.). Each chamber was equipped with a houselight, tone generator, and an LCD touchscreen (EloTouch, Menlo Park, CA) in lieu of the wall opposing the pellet dispenser. The pellet dispenser delivered single 45-mg dustless sucrose pellets (BioServ, Frenchtown, NJ) . Custom software (Ryklin Software Inc., NY) controlled touchscreen stimuli presentation, tone generation, houselight illumination, and pellet dispensation.
Behavioral training
General All behavioral training and testing took place five times per week, one to two times per day, with each session lasting a maximum of 45 min. Methodological details are the same as outlined in Izquierdo et al. (2010) , with the exception of the added tally of omissions in the present study (see details below). Time spent in each phase was not determined a priori, but was instead dependent on each individual animal's performance. Criterion for advancement for each phase of pretraining was 60 correct nose pokes to the stimulus within 45 min, on each of two consecutive days. During discrimination learning, posttreatment discrimination retention, and reversal learning testing, criterion for advancement to the next stage of testing was a minimum of 85 % correct trials for two consecutive days, with a minimum of 60 correct nose pokes. Only small areas (2.5-cm diameter circles) on the touchscreens underlying the stimuli were sensitive to nose poking, while all other areas remained unresponsive.
Food restriction and acclimation to food rewards When rats reached a minimum body weight of 275 g, they were foodrestricted to no less than 85 % of their free-feeding body weight to ensure motivation to work for food, while water was available ad libitum. On each of the 2 days prior to the start of testing, rats were fed 20 sucrose pellets in their home cage to accustom them to the food reward.
Autoshaping and pretraining Autoshaping began with the display of white graphic stimuli on the black background of the touchscreen, the disappearance of which was paired with the onset of a "reinforcer event": a sucrose pellet, a 1-second (s) tone, and a 1-s illumination of the houselight. Criterion for autoshaping occurred when rats ate 60 sucrose pellets within 30 min for each of two consecutive days. Pretraining consisted of different stages, in which the rats progressively learned to nose poke a stimulus (i.e., a white circle), initiate a trial, and were punished for nose poking the incorrect (blank) window on the touchscreen. Punishment consisted of the absence of a reinforcer event and an inability to initiate a new trial for 5 s. A "correction trial" occurred after a punishment and consisted of the same left/right presentation of stimuli (in this case, white circle and blank screen) until the rat nose poked correctly. If the rat did not nose poke either stimulus within 40 s of its appearance onscreen, an omission was recorded, in which the following occurred: (1) the trial timed out, (2) a punishment occurred, (3) an omission tallied, and (4) a new trial initiated.
Visual discrimination learning With the exception of added omission tally in the present study, visual discrimination learning was identical to procedures outlined in Izquierdo et al. (2010) . Briefly, two novel equiluminescent stimuli (S A and S B ) were presented concurrently with predetermined reinforcement contingencies, used to allow either a reward event as a result of nose poking the correct stimulus (S+) or a punishment as a result of nose poking the incorrect stimulus (S−). Stimuli presentation (i.e., left/right presentation of the S+) occurred pseudorandomly. Stimulus assignment
) was counterbalanced across treatment groups. Following successful completion of this phase (85 % correct trials, minimum of 60 correct responses, for each of two consecutive days), rats were removed from food restriction 5 days prior to drug treatment to ensure a healthy body weight and to mitigate any possible interaction with mAMPH.
Drug treatment
Rats were given injections of D-mAMPH (Sigma, St. Louis, MO; s.c.) or physiological SAL solution (1 ml/kg, s.c.) on a clean room procedure table in their housing room, five times per week for 4 weeks, between 1200 and 1500 hours. A 4-week treatment regimen was chosen for its similarity to other mAMPH-and amphetamine-escalating protocols (Featherstone et al. 2008; Fletcher et al. 2007; Madden et al. 2005; Segal and Kuczenski 1997) . There were three treatment groups: (1) mAMPH escal group (n016) received mAMPH, starting at 0.3 mg/kg and escalating in 0.3 mg/kg increments per day, culminating in 6 mg/kg, (2) mAMPH single group (n09) received SAL for 4 weeks with a single dose of 6 mg/kg mAMPH only on the last day of treatment, and (3) the SAL group (n06) received SAL for the duration of treatment. The largest dose of 6 mg/kg was chosen because it was found to be well-tolerated by our intermittently food-restricted animals. In addition to monitoring body weight, food consumption was assessed daily throughout treatment.
Posttreatment testing
Retention and reversal learning Following 3-5 days of rest after treatment with mAMPH, rats were put back on food restriction and tested for retention of the initial discrimination contingencies, using procedures identical to the visual discrimination learning phase, above. Upon reaching criterion on this phase (85 % correct trials for each of two consecutive days), the rats were tested on a reversal of the reward contingencies. Parameters for the reversal phase were identical to the visual discrimination learning (above), with the exception that the reward contingencies were reversed.
[
I]RTI-55 binding to DAT and SERT
Rats were euthanized between 6 and 8 weeks after mAMPH or SAL treatment with an overdose of sodium pentobarbital (250 mg/kg, i.p.) and decapitated, and their brains were removed and frozen at −20°C by immersion in isopentane. Twenty-micrometer-thick coronal sections were cut on a cryostat at the level of the anterior striatum (AP coordinates +1.9 to +1.0 mm, relative to bregma) and prefrontal cortex (AP coordinates +3.7 to +2.8 mm, according to Paxinos and Watson (2005) ), thaw-mounted on Vectabondtreated glass slides and stored at −20°C until used for autoradiographic determination of DAT or SERT binding, respectively. For the determination of striatal DAT binding, warmed slides removed from the −20°C freezer were preincubated in a solution of assay buffer (10 mM NaPO 4 , 120 mM NaCl, and 100 mM sucrose) for 5 min to remove endogenous ligands that could interfere with subsequent radioligand binding. After preincubation, the sections were incubated in a solution of assay buffer containing 25 pM [ (Boja et al. 1992) . The sections were then rinsed twice for 2 min each at 4°C in assay buffer then once for 10 s in 4°C distilled water. The rinsed slides were then rapidly dried under a stream of heated air. Determinations of frontoparietal cortex SERT were performed in much the same way as those for striatal DAT except that fluoxetine was omitted. Values obtained represented mean measurements taken from both hemispheres in a total of four sections per animal. For DAT analysis, the images were first divided into caudate-putamen (CP) and whole nucleus accumbens septi samples. The CP was then subdivided into four subregions: dorsomedial, dorsolateral, ventromedial, and ventrolateral parts, which were separately quantified for binding. For SERT analysis, samples encompassing all cortical layers were taken in infralimbic, prelimbic, cingulate, motor, somatosensory, insular, and orbitofrontal cortical regions.
Data analyses
Data were analyzed using StatView software. Statistical significance was noted when p values were equal to or less than 0.05, and a trend towards significance was noted when p values were 0.06-0.08. Data were collected for three phases: (1) initial visual discrimination learning, (2) posttreatment retention, and (3) posttreatment reversal learning. Performance was analyzed on five measures: (1) sessions to criterion, (2) accuracy (i.e., percent of correct trials of total trials), (3) perseveration (i.e., number of consecutive errors), (4) attention (i.e., number of omissions or trials initiated, but no nose poke), and (5) effort (i.e., total trials or nose pokes committed, correct or incorrect).
Overall learning analyses were conducted using individual ANOVAs for mean performance on discrimination, retention, and reversal learning phases on the measures described above. "Sessions to criterion" represents the number of sessions required to meet the criterion of two consecutive sessions of 85 % correct trials and does not include the criterion run. To assess learning over time, analyses were conducted for the first 14 sessions for discrimination and first 20 sessions of retention and reversal learning, using repeated-measures ANOVAs (rmANOVA). These periods were selected for analyses because the slowest learner reached criterion in these time frames. If a subject reached criterion before the 14-or 20-session time frame, the mean of the last two sessions (the criterion run) was carried forward for this subject (Izquierdo et al. 2010) . Early reversal learning across session was also analyzed using rmANOVAs, as was rat body weight and food consumption across the day of treatment. DAT and SERT values, reported as the percentage of the average SAL-treated values for each region, were also analyzed using rmANOVA. When ANOVAs and rmANOVAs resulted in significant main effects and interactions, respectively, Bonferroni post hoc pairwise comparisons were conducted.
Results
Pretreatment visual discrimination learning Rats learned the visual discrimination task in an average of 3.94 (±0.60) sessions. An ANOVA revealed no group differences in sessions to criterion (SAL04.0±1.27, mAMPH single 0 4.56±1.23, and mAMPH escal 03.56±0.84). There were no significant differences on any other measure of performance in the destined treatment groups, including percent correct, correction trials, omissions, or total trials committed. Treatment group means are shown in Table 1 .
There were also no differences in learning according to stimulus assignment (i.e., which of the two stimuli is rewarded) (mean sessions to criterion: S A + S B − 05.13±1.33, S A − S B + 05.47±1.41). Thus, data for stimulus assignment were collapsed for all subsequent analyses. Initial visual discrimination learning curves for destined treatment groups are shown in Fig. 1a .
Body weight during treatment Rats quickly gained weight during intermittent periods of free feeding. However, rats receiving extended mAMPH treatment displayed attenuated body weight over the period of treatment (average weight in grams: SAL0499.25±6.06 and mAMPH escal 0461.7±4.90). A rmANOVA revealed a significant interaction of treatment × day on body weight (F 19, 342 09.31, p<0.01). No significant effect of treatment was observed, though there was a significant effect of day on body weight (F 19, 342 056.99, p<0.01). Despite the difference in body weight across day, treatment groups did not differ in food consumption, nor was there an interaction of treatment × day on food consumption. Because the mAMPH single group was treated across 19 days of SAL and only 1 day of mAMPH, they constituted part of the SAL group for the repeatedmeasures analysis. Data are shown in Fig. 2 .
Effect of mAMPH on retention of visual discrimination Upon resuming behavioral testing after treatment, rats were tested on their retention of the original stimulus assignment. Rats performed the retention test to criterion in an average of 6.04 (±0.99) sessions. An ANOVA revealed no treatment group differences in sessions to criterion (SAL 08.00 ± 1.90, mAMPH single 07.00±2.64, and mAMPH escal 04.36±2.87). There were also no treatment group differences on any other performance measure including percent correct, correction trials, omissions, or total trials committed. Similarly, rmANOVAs across 20 sessions of retention testing revealed no significant group differences or interactions on these measures. Treatment group means are shown in Table 1 .
Effect of mAMPH on reversal learning Upon reaching criterion on the original stimulus assignment, rats were tested on a reversal of the reward contingency. The rats reached the reversal learning criterion in an average of 18.33 (±1.82) sessions. An ANOVA revealed no treatment group differences in sessions to criterion. However, ANOVAs resulted in significant differences in percent correct (F 2, 14 05.26, p00.02) and total trials committed (F 2, 14 04.74, p00.03). Bonferroni post hoc tests with a corrected alpha level of 0.02 revealed differences between the mAMPH single and SAL groups (p<0.01) for both of these measures with a trend toward a significant difference between the mAMPH escal and SAL groups (p≤0.08). MAMPH-treated groups were not, however, significantly different from each other.
A rmANOVA across 20 sessions of reversal learning revealed a significant main effect of treatment group on percent correct (F 2, 21 03.69, p00.04). Bonferroni post hoc tests with corrected alpha level of 0.02 revealed a significant difference between the mAMPH single and SAL groups (p<0.02), with a trend towards a significant difference between the mAMPH escal and SAL groups (p 00.05). Here again, no significant differences were observed between mAMPH escal and mAMPH single groups, indicating that mAMPH-treated rats displayed lower percent correct than SAL rats (Fig. 1b) . There was no significant treatment group × testing session interaction. A Fig. 1 Mean percent correct by session for pretreatment discrimination learning and posttreatment reversal learning. Left panel: There were no significant destined group differences in pretreatment discrimination learning accuracy. Right panel: Both mAMPH-treated groups performed similarly on posttreatment reversal learning, exhibiting attenuated accuracy (n016 mAMPH escal , n09 mAMPH single , n06 SAL) rmANOVA revealed a trend toward significance on total trials (F 2, 21 02.94, p<0.08), suggesting a difference between mAMPH single and SAL rats with both mAMPH groups performing worse than SAL, but no interaction with session. Additional rmANOVAs revealed no significant group differences on correction trials and omissions or a significant treatment × session interaction for either of these measures. Treatment group means are shown in Table 1 .
Effect of mAMPH on early reversal learning Consistent with previous studies in our lab (Izquierdo et al. 2010) , we explored differences in early reversal learning for three reasons: (1) initial or "early" reversal learning requires greater inhibitory control (Jones and Miskin 1972) ; (2) DA manipulations selectively affect early reversal learning using touchscreen response methodology in rodents (Izquierdo et al. 2006) ; and (3) DA changes as a result of mAMPH administration are more likely to be pronounced in earlier testing sessions, with some recovery occurring as timesince-treatment increases (Cass and Manning 1999; Friedman et al. 1998; Melega et al. 1997) .
As expected in reversal learning, rats initially (preferentially) select the stimulus associated with reward according to the previous reward contingency, as evidenced by their below-chance performance. A rmANOVA on the first three sessions of reversal learning accuracy revealed a significant effect of treatment group (F 2, 21 04.31p<0.03) and a significant interaction of treatment group × session (F 4, 42 02.65p < 0.05). Bonferroni post hoc tests with corrected alpha level of 0.02 confirmed a significant difference between mAMPH single and SAL rats (p<0.01) and a trend towards a difference for mAMPH escal and SAL rats (p00.07), with both mAMPH single and mAMPH escal performing worse than SAL, and that the mAMPH treatment groups were not significantly different from each other. Individual ANOVAs for the first three sessions revealed differences only on day 3 (F 2, 14 03.66, p00.05), but were not present on session 1 or 2. Post hoc tests reveal only a trend towards significance between mAMPH single and SAL (p00.03) and mAMPH single and mAMPH escal (p00.03). Data are shown in Fig. 3 .
Similarly, rmANOVAs on the first 3 days of reversal learning revealed no effect of treatment for number of correction trials or number of omissions, but there was a trend towards significance for total trials committed (F 2, 21 02.93, p<0.08). Bonferroni post hoc tests suggest both mAMPH groups committed fewer trials than SAL rats. There were no interactions of session × treatment group for number of correction trials, number of omissions, or total trials committed.
Effects of mAMPH on [
125 I]RTI-55 binding to DAT and SERT A rmANOVA revealed no overall treatment group differences for striatal DAT binding (mean levels of DAT, as a percent of SAL control values; mAMPH single 087.48± 2.82, mAMPH escal 099.38±1.64, and SAL0100.00±1.58), but the interaction of treatment group × subregion was highly significant (F 10, 105 03.73, p < 0.01). Bonferroni follow-up tests (with a corrected alpha level of p<0.02) surprisingly show the primary difference to be between mAMPH single and mAMPH escal , though the difference did not reach statistical significance (p<0.09). A follow-up ANOVA examining each striatal subregion individually revealed a significant group difference only in the ventrolateral CP (Fig. 4) (F 2, 21 04.15, p00.03; mean DAT levels: mAMPH single 077.44±7.86, mAMPH escal 095.58±4.31, and SAL0100.00±3.77). Bonferroni follow-up tests suggest a trend towards significant differences between mAMPH single and mAMPH escal (p<0.03) and a significant difference between mAMPH single and SAL (p<0.02) in this region. All other striatal subregions showed no significant group differences. A rmANOVA revealed no group Fig. 2 Mean body weight (in grams) during treatment. There was a significant interaction of treatment group by day on body weight. Because the mAMPH single group was treated across 19 days of SAL and only 1 day of mAMPH, they constituted part of the SAL group for this comparison (n010 mAMPH escal , n010 SAL) Fig. 3 Mean percent correct for early (posttreatment) reversal learning differs between mAMPH-and SAL-treated groups. Both mAMPHpretreated groups scored lower percent correct on early (sessions 1-3) reversal phase compared to SAL (n016 mAMPH escal , n09 mAMPH single , n06 SAL). Bars represent group means±SEM; *p00.05 and **p00.01 versus SAL differences for frontoparietal SERT (mean levels of SERT: mAMPH single 0101.07±4.03, mAMPH escal 0105.44±2.37, and SAL0100.00±1.87), nor a significant group × region interaction.
Discussion
We report the novel finding that single and escalating doses of mAMPH exert similar effects on reversal learning. Performance of both mAMPH groups was statistically indistinguishable for measures of accuracy (percent correct) and effort (total trials committed), with a more pronounced impairment in the rats receiving a single injection of mAMPH. This impairment was specific to reversal learning: retention of the pretreatment discrimination was unaffected after either brief or extended treatment. Our findings also substantiate the view that cognitive deficits can occur after mAMPH even in the absence of appreciable decreases in DAT and SERT binding. Interestingly, even though mAMPH escal rats perform as poorly as the mAMPH single group on reversal learning, only the mAMPH single rats demonstrated any measured DAT changes.
Single-dose versus single-day binge
Several previous experiments from our laboratories have examined the cognitive and neurochemical sequelae of single-day mAMPH binge administration (Belcher et al. 2008; Izquierdo et al. 2010; Kosheleff et al. 2011 ), but to our knowledge, this is the first study to examine such effects in rats receiving a single mAMPH injection. The 4×2-mg/kg binge mAMPH regimen used previously differs from the present mAMPH single regimen because it delivered a larger total quantity of mAMPH over a protracted period (during binge, doses are separated by 2 h). Despite these differences, measures of reversal learning, effortful behavior, and striatal DAT after a single mAMPH dose collected in the present study appear to be quite similar to measures obtained after a 4×2-mg/kg binge (Izquierdo et al. 2010; Kosheleff et al. 2011 ).
Reversal learning
Until recently, many rodent studies of mAMPH exposure (Marshall et al. 2007; Schröder et al. 2003 ) and selfadministration (Reichel et al. 2011 ) have pointed to greater specificity for this drug's effects on recognition memory. Our observation that both brief and extended mAMPH selectively affect reversal learning provides additional evidence to that already gathered in monkeys (Groman et al. 2012 ) that this task may be a particularly sensitive assay for mAMPH effects on an aspect of cognition phenotypically related to compulsive drug use (Izquierdo and Jentsch 2012; Lucantonio et al. 2012) .
During reversal learning, we also observed behavior indicative of diminished effort, as assessed by fewer overall trials committed or "nose pokes" on the touchscreen by the mAMPH-treated groups compared to SAL. A pattern of fewer attempts at reward during reversal learning is consistent with previous results from our lab where rats treated with a 4×2-mg/kg binge regimen were found to be work averse on an effort discounting task at increased work demands (Kosheleff et al. 2011) . Analogously on the reversal task in the present study, we showed no deficits on the familiar retention phase of the task, but upon reversal of the reward contingencies (i.e., upon increasing difficulty), mAMPH single rats (and to a slightly lesser degree, mAMPH escal rats) show reduced effort to initiate trials and attempt to procure the food reward. 
Monoaminergic markers
Animal studies have clearly established that single-day binge administration of moderate-to-high doses of mAMPH decreases striatal DA content, DAT protein and binding, as well as other markers of dopaminergic terminal integrity (e.g., tyrosine hydroxylase protein) (Cadet et al. 2009; Fleckenstein et al. 2009; Yamamoto et al. 2010) . The dosing regimens employed here were below the range typically used to achieve dopaminergic neurotoxicity (three or four injections of 4-10 mg/kg, spaced at ca 2-h intervals). Nevertheless, our finding of a small but significant DAT loss in the mAMPH single dose group stands in contrast to the complete absence of DAT loss in the mAMPH escal group. In addition, frontal cortical SERT was not affected in either group, suggesting that (1) frontocortical SERT systems are more resistant than striatal DAT to damage by the dosing regimens employed and (2) other neural components not measured here may be involved in the impairment. The relatively low expression of SERT in the striatum and DAT in frontoparietal cortex precluded their quantification in these experiments. However, the present data suggest that cognitive changes (attenuated reversal learning) can occur in the absence of robust monoaminergic changes in either mAMPH treatment group and instead may reflect DA dysregulation (Cools et al. 2009; Jocham et al. 2009 ). Our present findings are consistent with a recent study showing that individual variation on reversal learning performance in mAMPH-treated monkeys could be accounted for by D2 dysregulation (Groman et al. 2012 ).
Conclusion
Our report of impaired reversal learning following brief and extended mAMPH adds to the list of cognitive impairments observed in the absence of appreciable monoaminergic toxicity. It is likely that mAMPH can affect cognition via mechanisms other than neurotoxicity (Belcher et al. 2006 (Belcher et al. , 2008 Reichel et al. 2011; Rogers et al. 2008) , and individual cognitive measures likely differ in their sensitivity to neuroplastic changes after mAMPH. Reversal learning may be particularly sensitive to mAMPH-induced neuroplasticity, whereas other tasks may be more resilient to perturbation. Future studies should be directed at discerning the etiology of mAMPH effects on reversal learning, specifically whether the primary impairment stems from reduced motivation (work aversion) or impaired reward learning.
